Researchers have developed a new approach, known as Dephosphorylation-Targeting Chimeras (DEPTACs), to specifically reduce hyperphosphorylated tau protein in Alzheimer’s disease and other tauopathies. The DEPTACs aim to target and bind to phosphorylated tau while recruiting phosphatase molecules to enhance dephosphorylation. This precise method avoids the potential toxic side effects of tau kinase inhibitors or phosphatase activators. Initial studies show promising results in cell and animal models of tauopathy, suggesting a potential therapeutic strategy for these debilitating diseases.
Link: https://doi.org/10.1016/j.scib.2024.01.019
